ライフサイエンスコーパス: alcohol withdrawal

1 mood states like anxiety experienced during alcohol withdrawal.

2 ement of the nicotinic cholinergic system in alcohol withdrawal.

3 trial, intranasal oxytocin potently blocked alcohol withdrawal.

4 ce of the Fkbp5 gene enhances sensitivity to alcohol withdrawal.

5 ptor availability during acute and prolonged alcohol withdrawal.

6 e 4 with a large effect on predisposition to alcohol withdrawal.

7 subspecialty consultations, and anticipated alcohol withdrawal.

8 o neuronal hyperexcitability observed during alcohol withdrawal.

9 especially for individuals with histories of alcohol withdrawal.

10 ounted for 68% of the genetic variability in alcohol withdrawal.

11 number of 22-kHz USVs observed during acute alcohol withdrawal and a KOR agonist (U50,488) resulted

12 of the negative affective state produced by alcohol withdrawal and abstinence, which is critical for

13 e medical ICU solely for treatment of severe alcohol withdrawal and b) to determine whether a strateg

14 es negative affective states induced by both alcohol withdrawal and conditioned stimuli as being prod

15 Patients with severe alcohol withdrawal and delirium tremens are frequently r

16 rasonic vocalizations (USVs) associated with alcohol withdrawal and KOR activation in adult male wist

17 pport the role of ceftriaxone in alleviating alcohol withdrawal and open a novel pharmacologic avenue

18 zenil uptake correlated with the severity of alcohol withdrawal and the number of days since the last

19 (KOR) system mediates phenotypes related to alcohol withdrawal and withdrawal-like negative affectiv

20 pendence (alcoholism not in remission and/or alcohol withdrawal) and sepsis, septic shock, and hospit

21 e admitted by a surgical service, have acute alcohol withdrawal, and be managed with pressure-control

22 trations, by drugs used for the treatment of alcohol withdrawal, and by taurine, an ingredient of cer

23 e in the management of seizures secondary to alcohol withdrawal, and in those due to theophylline or

24 , as determined by M30 levels, occurs during alcohol withdrawal, and survival data point toward a nov

25 und to be increased, or not affected, during alcohol withdrawal, and to show no differences from CON

26 fore tested whether GDNF in the VTA reverses alcohol withdrawal-associated DA deficiency and/or posse

27 06) in heavy drinkers primarily admitted for alcohol withdrawal before and after alcohol detoxificati

28 ble for 26% of the genetic variance in acute alcohol withdrawal convulsion liability to a >35 centimo

29 a medical ICU solely for treatment of severe alcohol withdrawal have a high incidence of requiring me

30 ntly increased glutamate levels during acute alcohol withdrawal in corresponding prefrontocortical re

31 Treatment of alcohol withdrawal in the intensive care unit mirrors th

32 or developing novel treatment approaches for alcohol-withdrawal-induced mood and anxiety disorders.

33 Alcohol withdrawal is associated with hypothalamic-pitui

34 indicating that MPDZ variants may influence alcohol withdrawal liability.

35 m is related to genetic differences in acute alcohol withdrawal liability.

36 Adjunctive dexmedetomidine for severe alcohol withdrawal maintains symptom control and reduces

37 m tremens, the most serious manifestation of alcohol withdrawal, occurs in approximately 5% of hospit

38 red either following short periods (24 h) of alcohol withdrawal, or 90 m following alcohol consumptio

39 or treating anxiety, epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia, and sedation a

40 f amygdala) and prevented the development of alcohol withdrawal-related anxiety in rats as measured b

41 interval-specific congenic lines, show that alcohol withdrawal severity is genetically correlated wi

42 reases in cell proliferation correlated with alcohol withdrawal severity, proliferation remained incr

43 the effect of Fkbp5 gene deletion in mice on alcohol withdrawal severity.

44 sed analyses also showed an association with alcohol withdrawal severity.

45 ere mapped that contain genes that influence alcohol withdrawal severity.

46 that this effect was more pronounced during alcohol withdrawal, suggesting that AdipoR2 signaling ma

47 lly, to investigate the effect of MT-7716 on alcohol withdrawal symptoms, Wistar rats were withdrawn

48 MT-7716 significantly attenuated somatic alcohol withdrawal symptoms.

49 be potential therapeutic agents in treating alcohol withdrawal symptoms.

50 BA(A)) receptor-facilitating agents suppress alcohol withdrawal symptoms.

51 ption (r42 = -0.32, P < .05) and more severe alcohol-withdrawal symptoms (r38 = -0.35, P < .05).

52 CIE is validated as a model for human alcohol withdrawal syndrome (AWS) by demonstrating incre

53 Alcohol withdrawal syndrome (AWS) is a potentially fatal

54 Alcohol withdrawal syndrome (AWS) symptoms include hyper

55 ine occurrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens in pati

56 Measures included occurrence of alcohol withdrawal syndrome and delirium tremens, injury

57 Alcohol withdrawal syndrome assessment and its treatment

58 ital length of stay, ICU length of stay, and alcohol withdrawal syndrome complications differed signi

59 Alcohol withdrawal syndrome developed in 0.88% (n = 246)

60 Trauma patients with alcohol withdrawal syndrome experience a high occurrence

61 factors, and screening tools associated with alcohol withdrawal syndrome in the ICU are reviewed.

62 The role of currently published alcohol withdrawal syndrome pharmacologic strategies (be

63 Alcohol withdrawal syndrome progressed to delirium treme

64 mia, baseline CIWA-Ar score, and established alcohol withdrawal syndrome risk factors.

65 rome complications differed significantly by alcohol withdrawal syndrome severity and were worse with

66 Mortality also significantly differed by alcohol withdrawal syndrome severity but was only greate

67 Before adjustment, alcohol withdrawal syndrome severity was associated with

68 Alcohol withdrawal syndrome severity was defined by CIWA

69 4%, and 0% by minimal, moderate, and severe alcohol withdrawal syndrome).

70 inical outcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical Institute With

71 s repeated alcohol use leading to tolerance, alcohol withdrawal syndrome, and physical and psychologi

72 ns, injury characteristics, risk factors for alcohol withdrawal syndrome, clinical outcomes, pharmaco

73 In patients with severe alcohol withdrawal syndrome, severe head injury also pre

74 a genetic effect of FKBP5 on the severity of alcohol withdrawal syndrome.

75 to withdrawal symptoms in ICU patients with alcohol withdrawal syndrome.

76 ere worse with more severe manifestations of alcohol withdrawal syndrome.

77 al pharmacologic strategies for treatment of alcohol withdrawal syndromes in the critically ill.

78 pathophysiology, diagnosis, and treatment of alcohol withdrawal syndromes in the intensive care unit

79 h the diagnosis and treatment strategies for alcohol withdrawal syndromes in the intensive care unit.

80 ns in dopamine transporter (DAT) sites after alcohol withdrawal, the role of DAT in influencing eithe

81 tribute to neuronal hyperexcitability during alcohol withdrawal, these findings suggest an important

82 O) and wild-type (WT) mice were assessed for alcohol withdrawal using handling-induced convulsions (H

83 Acute alcohol withdrawal was accompanied by downregulated GR m

84 trexone-gabapentin group, while a history of alcohol withdrawal was associated with better response i

85 Short-term alcohol withdrawal was associated with the recovery of l

86 uroadaptations in GABAA receptor levels over alcohol withdrawal will provide critical insights for th

87 aptive changes in HPA axis regulation during alcohol withdrawal with concomitant effects on withdrawa

88 We report that alcohol withdrawal with or without concurrent tobacco sm

89 he observed increase in HDAC activity during alcohol withdrawal with the HDAC inhibitor, trichostatin

90 , which confirms capture of a gene affecting alcohol withdrawal within the <1 cM interval.